Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

A number of other brokerages have also issued reports on KPTI. Jefferies Group LLC reissued a “buy” rating and set a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday, August 10th. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Royal Bank Of Canada reissued a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus price target of $15.50.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at $11.07 on Tuesday. Karyopharm Therapeutics has a 1 year low of $6.27 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts expect that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.

WARNING: “Karyopharm Therapeutics Inc. (KPTI) Stock Rating Lowered by Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/karyopharm-therapeutics-inc-kpti-stock-rating-lowered-by-zacks-investment-research/1689160.html.

In related news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 10,695 shares of company stock valued at $118,950. 14.71% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in Karyopharm Therapeutics by 0.7% in the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after acquiring an additional 308 shares during the period. ProShare Advisors LLC lifted its stake in Karyopharm Therapeutics by 8.0% in the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock worth $246,000 after acquiring an additional 2,021 shares during the period. American International Group Inc. lifted its stake in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after acquiring an additional 2,836 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Karyopharm Therapeutics by 4.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after acquiring an additional 3,762 shares during the period. Finally, Swiss National Bank lifted its stake in Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after acquiring an additional 4,000 shares during the period. 59.14% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.